Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

871
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
871
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

14.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.2K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

2.1K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.1K
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Documented Adverse Reactions to Different Intravenous Iron Formulations in the Veterans Health Administration: A 10-Year Retrospective Study.

Pharmacoepidemiology and drug safety·2026
Same author

Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines.

bioRxiv : the preprint server for biology·2026
Same author

Enhancing Perioperative Prescription Opioid Risk Mitigation Through Pharmacist Intervention.

Journal of pain & palliative care pharmacotherapy·2026
Same author

Albumin Reduces Hepatic Steatosis and Inflammation in High-Fat-Diet-Fed Mice.

International journal of molecular sciences·2025
Same author

Enhancing Drug Hypersensitivity Reaction Documentation Through a Clinical Surveillance Tool.

Journal for healthcare quality : official publication of the National Association for Healthcare Quality·2025
Same author

High-Fidelity In Vitro Packaging of Diverse Synthetic Cargo into Encapsulin Protein Cages.

Angewandte Chemie (International ed. in English)·2025

Related Experiment Video

Updated: Sep 12, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Increasing statin prescribing through a pharmacogenomics-guided initiative.

Claire Rennie, Mary Roads, Bridger Bright

    Journal of the American Pharmacists Association : Japha
    |August 10, 2025
    PubMed
    Summary

    Pharmacogenomics testing helps Veterans start statin therapy, improving adherence and tolerance. This genetic approach guides personalized statin prescriptions, overcoming intolerance concerns.

    More Related Videos

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    13.5K
    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    10.2K

    Related Experiment Videos

    Last Updated: Sep 12, 2025

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    14.7K
    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    13.5K
    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    10.2K

    Area of Science:

    • Pharmacogenomics
    • Clinical Pharmacy
    • Quality Improvement

    Background:

    • Suboptimal statin therapy utilization is linked to adverse effect concerns and genetic predispositions to statin intolerance.
    • Personalized medicine approaches are needed to optimize cardiovascular disease prevention strategies.

    Purpose of the Study:

    • To implement pharmacogenomics testing for Veterans to guide statin therapy decisions.
    • To increase appropriate statin prescribing within a Veterans Affairs Health Care System (VAHCS).

    Main Methods:

    • A quality improvement initiative involved pharmacists offering pharmacogenomics testing and statin initiation via personalized phone calls.
    • Patient adherence and tolerability were assessed at least four weeks post-statin initiation.

    Main Results:

    • Out of 107 patients contacted, 50 initiated statin therapy, with 45 (90%) completing pharmacogenomics testing for guided prescriptions.
    • A majority of patients (72%) reported good adherence and tolerance to statin therapy after four weeks.

    Conclusions:

    • Pharmacogenomics testing can enhance patient-centered discussions and shared decision-making in statin therapy initiation.
    • Genomic guidance may improve the successful implementation of statin therapy in clinical practice.